Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research intensifies for treatment of PAD, says Sage
According to the report, gene, protein and cell therapies to induce arteriogenesis (angiogenesis) are the hot new areas of research for both IC and CLI. Arteriogenesis, also known
According to the report, gene, protein and cell therapies to induce arteriogenesis (angiogenesis) are the hot new areas of research for both IC and CLI. Arteriogenesis, also known
The Synapt HDMS system is reported to be the only commercial instrument to incorporate high efficiency ion mobility separation in a dual ionization mass spectrometer giving scientists maximum
The final purchase price consisted of $123.2 million cash and approximately 251,300 shares of Inverness common stock. In addition, existing options to purchase BBI stock have been assumed
The drugs that received positive opinions from the COMP were: Centocor’s (Johnson & Johnson) allogeneic human umbilical cord tissue-derived cells for the treatment of retinitis pigmentosa; JJGConsultancy’s ammonium
The trial is a 24-week, double-blind, placebo-controlled, randomized study comparing 60mg of denufosol inhaled three times daily to placebo in approximately 350 cystic fibrosis (CF) patients with FEV1
Non-GAAP adjusted earnings from continuing operation per ADS increased by about 80% year-over-year to about RMB15.8 for fiscal 2008. For the fourth quarter of fiscal 2008, Revenues from
All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment. Based on this assessment, two patients remain on study drug beyond the original
The restructuring is expected to streamline the company, consolidate corporate functions, and strengthen decision-making and execution within the business units. Approximately 150 positions have been eliminated as a
This multicenter, open, non-comparative, Phase III study showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of
Sylvie Gregoire, president of Shire HGT, the Shire business unit focused on genetic diseases, said: “The approval of Elaprase in Mexico marks a significant milestone because for the